Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference

Rhea-AI Summary

Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. The company's CEO and Chairman, John Yu, MD, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Interested participants can register for meetings by contacting John Perez at jperez@dboralcapital.com.

News Market Reaction – KAPA

+0.19%

+0.19% Session move

In the trading session that priced this news, KAPA gained 0.19%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.

John Yu, MD, CEO and Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET).

To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.

About Kairos Pharma, Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) aims to work at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.

About D. Boral Capital
D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.

D. Boral Capital is a leader on Wall Street, having aggregated over $25 billion in capital across approximately 350 transactions through various product types.

For further information:
Kairos Pharma, Ltd.
Louie Toma
Investor Relations
774-291-6000
investors@kairospharma.com
www.kairospharma.com

Source: Kairos Pharma, Ltd.

FAQ

When is Kairos Pharma (KAPA) participating in the D. Boral Capital Conference?

Kairos Pharma will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City.

Who will represent Kairos Pharma (KAPA) at the D. Boral Capital Conference?

John Yu, MD, CEO and Chairman of Kairos Pharma, will represent the company at the conference.

What is the schedule for one-on-one meetings with Kairos Pharma (KAPA) management?

One-on-one meetings will be held on May 14th from 9:00 A.M. to 3:00 P.M. (ET) at The Plaza Hotel in New York City.

How can investors register for meetings with Kairos Pharma (KAPA) management?

Interested parties can register for one-on-one meetings by contacting John Perez at jperez@dboralcapital.com.